The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2015Pre-clinical Evaluation of Neuroprotective Small Molecule Erythropoietin Receptor Agonists in the Treatment of Parkinson’s Disease Supplement
Study Rationale:
STATegics has discovered small molecules that selectively activate the tissue-protective erythropoietin (EPO) receptor, but not the EPO receptor that plays a role in... -
Research Grant, 2016Novel Quantification in Parkinson’s Disease Neurochemical Imaging
Promising Outcomes of Original Grant:
We hypothesized in the original funded grant that evaluation of texture and variability, beyond conventional averaging of voxel (element of space) intensities... -
Dyskinesia Challenge, 2012Combined Therapy with Amantadine and Fenobam for Levodopa-induced Dyskinesia
Objective/Rationale:
Amantadine is currently the only available medication to treat levodopa-induced dyskinesia: involuntary, jerky movements caused by long-term use of the Parkinson’s drug levodopa... -
Research Grant, 2013A New Pharmaceutical Target for Mono and Add-on Therapy in Parkinson’s Disease
Objective/Rationale:
We are targeting a molecule, for the first time in Parkinson’s research, that is only present in the human brain’s motor circuitry and that we believe will respond to... -
Biosample and Tissue Resource, 2013From Genetic Risk Toward Genetic Prognosis
Objective/Rationale:
The progression and prognosis of Parkinson’s disease (PD) varies considerably between individual patients — ranging from a manageable, functional decline to an aggressive course... -
Research Grant, 2014Role of LRRK2 in Dopamine Modulation of Striatal Glutamate Transmission
Objective/Rationale:
Many of the motor symptoms in Parkinson’s disease (PD) are attributed to a deficit of the neurotransmitter dopamine in the brain region called the striatum. Recent studies show...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.